NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) is positioned to be a leading vertically integrated supplier of lithium-ion battery anode material for electric vehicles, analysts at Capital Access believe.
The firm has initiated coverage on NextSource Materials, which is ramping up to Phase 1 production of 17,000 tons per year at its Molo graphite mine in Madagascar and the final permitting process for its first Battery Anode Facility in Mauritius.
Gold miners could experience a surge in value beyond the first quarter of 2024 as prices for the precious metal have strengthened since the beginning of 2024, according to Jefferies.
Analysts suggests a potential average increase of 14% in target prices for gold miners despite a softer outlook for first quarter results.
In a bullish endorsement for Arecor Therapeutics PLC (AIM:AREC), Panmure Gordon has issued a 'buy' recommendation, underpinning a significant upside potential with a target price of 539p — over four times the current share price of 132p.
Known for its innovative diabetes treatments, Arecor is expected to pick up royalties from AT220 product, its new insulin formulation, that could generate a sustainable revenue stream for the company.
Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) should see positive margin impacts emerging from a focus on higher-quality revenue streams, says house broker Shore Capital.
“The market opportunity appears promising spanning across various venues and geographies, and we see ACSO as well place to capture a greater share through leveraging its now broader solutions suite”.
A new exchange-traded commodity (ETF) fund focused on gold produced solely from mines with the highest ESG ratings has been launched in London.
SMO Physical Gold ETC (LSE:BARS) tracks gold bars from mine to vault, only using mines that have been independently audited and accredited with the highest responsibility standard to provide social, environmental and cultural support to local communities
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has secured a European patent for its CellKeep slide, with US intellectual property protection from the US set to follow soon.
This innovative device reduces cell loss by over 70% during the microscopy analysis of circulating tumour cells (CTCs), a common challenge in clinical oncology and pharmaceutical research.